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See Article, pages 652–657The efﬁcacy of antiviral therapy for chronic hepatitis C (CHC) has
improved signiﬁcantly in the last decade. Currently, with the use
of pegylated interferon and ribavirin, around 50% of treated
patients will achieve a sustained virological response (SVR)
[1,2]. However, there are certain groups of patients in whom
treatment is still a challenge. One of these groups is constituted
of individuals with advanced ﬁbrosis or cirrhosis. Several reasons
explain the difﬁculty in treating these patients. First, the efﬁcacy
of antiviral therapy in this group is signiﬁcantly lower than in
patients with mild disease. The presence of cirrhosis has not
always been an independent factor for non-response in most ran-
domized clinical trials, and the explanation for this is most likely
due to the small proportion of individuals with bridging ﬁbrosis
or cirrhosis included in these studies. Recent data obtained from
a large number of individuals included in three randomized inter-
national studies [3] show that SVR rates decreased progressively
from 60% in genotype 1/4 patients without advanced ﬁbrosis to
51% in those with bridging ﬁbrosis and 33% in those with cirrho-
sis (p <0.01); the same ﬁgures for genotype 2/3 patients were
76%, 61%, and 57%, respectively (p <0.01). Data from the HALT-C
study further support that SVR rates are signiﬁcantly lower in
patients with advanced ﬁbrosis and particularly with cirrhosis
[4]. Apart from a decreased efﬁcacy, patients with advanced liver
disease are older in comparison to individuals with mild chronic
hepatitis and thus, tolerance to therapy is poor. Furthermore,
some adverse events (such as neutropenia, anemia or thrombocy-
topenia) occur more frequently due to the presence of portal
hypertension. Importantly, co-morbidities such as diabetes,
hypertension or depression are more prevalent in these individu-
als. Some of these co-morbidities (such as the presence of diabe-
tes) seem to directly inﬂuence the rates of viral clearance; other
associated diseases decrease treatment adherence or represent
relative contraindications that make antiviral therapy particu-
larly difﬁcult. All together, treating physicians are less motivated
to indicate antiviral treatment in patients with CHC and advanced
liver disease.Journal of Hepatology 20
*Corresponding author. Address: Liver Unit, Hospital Clinic, Villarroel 170,
Barcelona 08036, Spain.
E-mail address: xforns@clinic.ub.es (X. Forns).In the last few years, a signiﬁcant amount of information
derived from retrospective studies supports the fact that HCV
clearance after antiviral therapy is associated with improved out-
comes in patients with established cirrhosis. Bruno and collabo-
rators [5] analyzed the effect of SVR in a cohort of 920 biopsy-
proven cirrhotic patients treated with interferon-alfa and fol-
lowed for a median of 96 months. Only 124 of them achieved
SVR. Multivariate analysis showed that non-SVR was associated
with a higher risk of liver-related complications, HCC and liver-
related mortality. Similar results were obtained by Veldt and col-
leagues [6], who performed a similar analysis in a cohort of 479
patients with chronic hepatitis C and advanced ﬁbrosis or cirrho-
sis (Ishak score 4–6) treated with interferon-based regimens and
followed for a median period of 2.1 years. Of these patients, 142
(30%) achieved SVR, which again was associated with a signiﬁ-
cant reduction in the hazard of events. In this study, however,
the improved outcome was mainly due to a decrease in the inci-
dence of liver decompensation; the authors did not show a signif-
icant reduction in HCC in patients who achieved SVR (but most
cases occurred in the non-responder group).
Models where hepatitis C progression is accelerated, such as
co-infection with the human immunodeﬁciency virus (HIV) and
hepatitis C recurrence after liver transplantation, further support
the above mentioned ﬁndings. In a recent cohort study carried
out in 11 HIV units in Spain [7], 711 co-infected patients who
started interferon plus ribavirin were followed-up for 2 years
after antiviral therapy. The incidence of overall mortality, liver-
related mortality, and liver decompensation were signiﬁcantly
lower in patients who achieved SVR compared to non-respond-
ers. In the transplant setting, recent data support a strong effect
of hepatitis C virus (HCV) clearance on disease progression, as
measured by improvement in the hepatic venous pressure gradi-
ent [8] and clinical outcomes [9].
The study by Cardoso et al. [10] includes 307 patients with
bridging ﬁbrosis or cirrhosis, who were followed for a period of
3.5 years; SVR was achieved in 33% of patients. Sustained virolog-
ical responders and non-responders were comparable at baseline
regarding age, sex, body mass index, alcohol intake, and the pres-
ence of diabetes. As expected, non-responders were mostly
infected with genotype 1, had a higher viral load, and poorer liver10 vol. 52 j 624–626
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function. The incidence rates per 100-person-years of HCC and
liver-related complications were 1.24 and 0.62 for sustained viro-
logical responders as compared to 5.85 and 4.16 for non-respond-
ers (p <0.01). Despite the fact that liver disease was more
advanced at baseline in non-responders, SVR was still indepen-
dently associated with better outcomes after adjusting for liver
function. The results obtained in this study are very similar to
those published by Bruno et al. and Veldt et al. There are, how-
ever, some weaknesses that are important to stress. As recently
derived from the HALT-C study [4], lower albumin, lower platelet
count, and higher total bilirubin are baseline factors indepen-
dently associated with the development of clinical events in
patients with advanced ﬁbrosis or cirrhosis. These variables were
signiﬁcantly different between SVR and non-responders in the
study by Cardoso. Though the differences in outcomes between
responders and non-responders are remarkable, the retrospective
design of this study (and others) weakens the conclusion that
viral clearance is independently associated with improved out-
comes. A second important point that deserves some discussion
is the high incidence of HCC in this French cohort: it is signiﬁ-
cantly higher than the incidence observed in the studies by Bruno
and Veldt [5,6]. One of the potential explanations suggested by
the authors is the high prevalence of diabetes in their cohort
(22%); diabetes has been associated with the development of
HCC [11]. However, the prevalence of diabetes is not different
from that reported in the HALT-C trial (24%) [12]. In the latter
study (which included more than 1000 hepatitis C virus-positive
patients with bridging ﬁbrosis or cirrhosis) the cumulative 5-year
HCC incidence was around 5.0%, clearly lower than the one
reported by Cardoso (20%) [13].
Besides the potential limitations of the study, growing evi-
dence supports a beneﬁcial effect of HCV clearance in patients
with advanced liver disease. The decrease in liver necroinﬂam-
matory changes and the regression (or stabilization) of liver
ﬁbrosis are probably key players in explaining the signiﬁcant
reduction in clinical decompensation after SVR. The latter is
directly related to the effect of viral clearance in portal pressure
[8]. The decreased incidence of HCC in patients who clear HCV
but are already cirrhotic, may be the result of several mecha-
nisms and potentially, of some biases in the design of the study
itself. As in any retrospective study, it is impossible to ensure that
all patients were equally screened and evaluated for the develop-
ment of HCC. In addition, some risk factors for HCC development
may not have been taken into account as has recently been sug-
gested with coffee consumption [14]. Finally, even if diagnosed
with cirrhosis, it might well be that the evolutionary stage is
not properly stratiﬁed. Prospective investigations have shown
that the intensity of portal hypertension, as measured by hepatic
vein catheterization, correlates with the HCC risk [15], and the
same correlation has been established with the less invasive
measurement of liver stiffness [16]. Nevertheless, leaving aside
these methodological questions that cannot be solved, it is worth
elaborating upon the possible pathophysiologic mechanisms that
may be involved in the beneﬁcial effect of HCV eradication for
prevention of HCC in patients with established cirrhosis. We have
now two experimental models in mice that reproduce the natural
history of liver disease leading to ﬁbrosis and cancer. The ﬁrst is
the platelet derived growth factor (PDGF) mouse model that
develops extensive ﬁbrosis leading to cirrhosis and ultimately
HCC [17]. The second consists of the liver-speciﬁc overexpression
of lymphotoxins alpha and beta that induces liver inﬂammationJournal of Hepatology 201and HCC, thus supporting the link between chronic inﬂammatory
events and cancer development [18]. If HCV eradication in
humans prevents further collagen deposition to a critical level,
we would have a potential ﬁrst hypothesis for its efﬁcacy. The
same applies to the reduction of the inﬂammatory milieu that
accompanies viral infection. Again, a critical degree of accumu-
lated damage or a speciﬁc hit would be needed to elicit the onco-
genic capacity and if this has not taken place prior to HCV
eradication, the necessary events for cancer transformation may
not take place. The majority of cancers are supposed to require
several simultaneous genomic events and it may be that effective
viral treatment can prevent the accumulation of hits responsible
for malignant transformation. While this wishful thinking turns
into reality, there are several advancements that indicate that
we are entering the era of molecular prediction of cancer risk
and prognosis. Interestingly, a recent study in hepatitis B patients
has shown that the risk of cancer and the efﬁcacy of interferon in
preventing HCC recurrence after surgical resection may be pre-
dicted by the speciﬁc miRNA proﬁle [19]. This correlation will
also be investigated in HCV patients, but it is relevant to recall
that disease recurrence is due both to metastatic spread and to
de novo oncogenesis. Since not all HCV cirrhotics develop HCC
during follow-up it is clear that current research will ultimately
deﬁne risk categories according to genomic proﬁling. This has
been recently evidenced for the risk of late recurrence after
HCC resection in HCV patients [20] and preliminary data suggest
that this may also be feasible for the ﬁrst HCC in cirrhotic patients
[21]. If this is conﬁrmed and validated, the patients in need for
HCC screening programs would have to be redeﬁned.
As a whole, there is a vast area of research ahead and there is
no doubt that, our current understanding of liver disease and can-
cer will become outdated in a few years. However, the beneﬁts of
viral eradication are not to be challenged as there are several
positive consequences that are currently well established. Phar-
maco-economic models analyzing the cost-effectiveness of anti-
viral therapy in cirrhotic patients will need to take into account
the reduction in clinical events in patients who clear HCV and,
in a few years, the impact of new anti-HCV drugs in treatment
efﬁcacy.
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